#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Athero Review / 2019 - 1

Psoriasis as a risk factor for cardiovascular events: case report

Czech version

Authors: Branislav Vohnout 1,2,3;  Jana Lisičanová 3;  Andrea Havranová 4
Authors‘ workplace: Ústav výživy, FOaZOŠ a Koordinačné centrum pre familiárne hyperlipoproteinémie, SZU v Bratislave 1;  Ústav epidemiológie LF UK, Bratislava 2;  Diabetologická ambulancia, Diabeda s. r. o., Bratislava 3;  Ústav klinického a translačného výskumu, Biomedicínske centrum SAV, Bratislava 4
Published in: AtheroRev 2019; 4(1): 44-48
Category:

Overview

Psoriasis is a chronic inflammatory skin disease characterized by Th cell dysfunction and overexpression of pro-inflammatory cytokines. The disease is associated with cardiometabolic risk factors, such as dyslipidemia, central obesity and insulin resistance. Possible mechanisms linking psoriasis and atherosclerosis are related not only to inflammation but include also metabolic derangement and lipoprotein abnormalities. Patients with psoriasis are at increased risk of cardiovascular disease, particularly those with severe psoriasis.

Keywords:

Psoriasis – Atherosclerosis

Sources
  1. Ross R. Atherosclerosis – An inflammatory disease. N Engl J Med 1999; 340(2): 115–126. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199901143400207>.
  2. Vohnout B, de Gaetano G, Donati MB et al. The Relationship between Dyslipidemia and Inflammation. In: M. Mancini M, Ordovas J, Riccardi G et al (eds). Nutritional and Metabolic Bases of Cardiovascular Disease. Blackwell Publishing 2011: 202–210. ASIN B005D7EPG0. ISBN 978–1-444–34788–3,
  3. Caiazzo G, Fabbrocini G, Di Caprio R et al. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows. Front Immunol 2018; 9: 1668. Dostupné z DOI: <http://dx.doi.org/10.3389/fimmu.2018.01668>.
  4. Šimaljaková M. Psoriáza – etiopatogenéza, klinický obraz a súčasné možnosti terapie. Dermatol Prax 2008; 2(2): 50–55.
  5. Christophers E, Mrowietz U. Psoriasis. In: Burgdorf WH, Plewig G, Wolff HH et al (eds). Braun-Falco ́s Dermatology. 3rd ed. Springer Medizin: Heidelberg 2009: 506–526. ISBN 978–3-540–29312–5.
  6. Benáková N. Psoriáza a současné léčebné možnosti. Interní medicína pro praxi 2005; 7(2): 88–91.
  7. Harrington CL, Dey AK, Yunus R et al. Psoriasis as a human model of disease to study inflammatory atherogenesis. Am J Physiol Heart Circ Physiol 2017; 312(5): H867–H873. Dostupné z DOI: <http://dx.doi.org/10.1152/ajpheart.00774.2016>.
  8. Nickoloff BJ. Skin innate immune system in psoriasis: friend or foe? J Clin Invest. 1999; 104(9): 1161–1164. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI8633>.
  9. Sajja AP, Joshi AA, Teague HL et al. Potential Immunological Links Between Psoriasis and Cardiovascular Disease. Front Immunol 2018; 9: 1234. Dostupné z DOI: <http://dx.doi.org/10.3389/fimmu.2018.01234>.
  10. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12(3): 204–212. Dostupné z DOI: <http://dx.doi.org/10.1038/ni.2001>
  11. Baumer Y, Ng Q, Sanda GE et al. Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis. JCI Insight 2018;3(1). pii: 97179. Dostupné z DOI: <http://dx.doi.org/10.1172/jci.insight.97179>.
  12. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol; 68(4): 654–662. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaad.2012.08.015>.
  13. Li RC, Krishnamoorthy P, DerOhannessian S et al. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin Exp Dermatol 2014; 39(1): 19–24. Dostupné z DOI: <http://dx.doi.org/10.1111/ced.12250>.
  14. Shibata S, Tada Y, Hau C et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol 2011; 164(3): 667–670. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2133.2010.10123.x>.
  15. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001;303(1–2):33–39.
  16. Mehta NN, Li R, Krishnamoorthy P et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012; 224(1): 218–221. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2012.06.068>.
  17. Sorokin AV, Kotani K, Elnabawi YA et al. Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis. Circ Res 2018; 123(11): 1244–1254. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.118.313608>.
  18. Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int J Mol Sci 2017; 19(1). pii: E58. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms19010058>.
  19. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296(14): 1735–1741. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.296.14.1735>.
  20. Parisi R, Rutter MK, Lunt M et al. [Identification and Management of Psoriasis Associated ComorbidiTy (IMPACT) project team]. Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. J Invest Dermatol 2015; 135(9): 2189–2197. Dostupné z DOI: <http://dx.doi.org/10.1038/jid.2015.87>.
  21. Ahlehoff O, Gislason GH, Jørgensen CH et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2012; 33(16): 2054–2064. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr285
  22. Raaby L, Ahlehoff O, de Thurah A. Psoriasis and cardiovascular events: updating the evidence. Arch Dermatol Res 2017; 309(3): 225–228. Dostupné z DOI: <http://dx.doi.org/10.1007/s00403–016–1712–1>.
  23. Ridker PM, Everett BM, Thuren T et al. [CANTOS trial group]. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377(12): 1119–1131. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1707914>.
  24. Piepoli MF, Hoes AW, Agewall S et al. [Authors/Task Force Members]. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 252: 207–274. <http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.037>.
  25. Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol 2007; 57(3): 529–531. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaad.2007.05.040>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Severe mixed dyslipidemia as a manifestation of hematological disease: case report
Nutraceuticals with hypolipidemic effect in clinical practice: a summary statement of the International expert panel of lipidologists prepared by the committee of the Czech society for atherosclerosis
An initiative to establish apheresis centers: indications for and performance of lipoprotein apheresis in the Czech Republic
Lysosomal acid lipase deficiency in differential diagnosis of familial hypercholesterolemia
Therapy of dyslipidaemia in patient with muscular dystrophy: case report
The effect of alirocumab on cardiovascular events: What did the ODYSSEY OUTCOMES Trial show?
Intensive management of dyslipidemia in very high-risk patients with PCSK9 inhibitors
Article was published in

Athero Review

Issue 1
2019 Issue 1
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#